KR910009268A - 금단 증후군의 억제 - Google Patents

금단 증후군의 억제 Download PDF

Info

Publication number
KR910009268A
KR910009268A KR1019900019028A KR900019028A KR910009268A KR 910009268 A KR910009268 A KR 910009268A KR 1019900019028 A KR1019900019028 A KR 1019900019028A KR 900019028 A KR900019028 A KR 900019028A KR 910009268 A KR910009268 A KR 910009268A
Authority
KR
South Korea
Prior art keywords
butyl
piperazinyl
pyrazole
pyrimidinyl
radical
Prior art date
Application number
KR1019900019028A
Other languages
English (en)
Other versions
KR950007230B1 (ko
Inventor
호로디 후리골라 꼰스딴사
후안 빠레스 꼬로미나스
Original Assignee
마뇨사스 바레라, 엔리께
라보라또리오스 델 독또르 에스떼버 쏘시에다 아노니마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 마뇨사스 바레라, 엔리께, 라보라또리오스 델 독또르 에스떼버 쏘시에다 아노니마 filed Critical 마뇨사스 바레라, 엔리께
Publication of KR910009268A publication Critical patent/KR910009268A/ko
Application granted granted Critical
Publication of KR950007230B1 publication Critical patent/KR950007230B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Flanged Joints, Insulating Joints, And Other Joints (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Lubricants (AREA)
  • Ceramic Products (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Surgical Instruments (AREA)
  • Paper (AREA)
  • Saccharide Compounds (AREA)

Abstract

내용 없음

Description

금단 증후군의 억제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (2)

  1. 디아제팡, 코카인, 알코올 및/또는 니코틴과 같은 벤조디아제핀의 사용 중지에 의해 유발되는 금단 증후군과 관련된 질병 치료를 위한 의약품의 제조를 위하여,
    상기 일반식(Ⅰ)에서, n이 1 내지 6이고, R이 수소원자, 할로겐, C₁ 내지 C₄의 저급 알킬 라디칼, 헤테로아릴라디칼, 설포 라디칼 또는 N-치환 또는 N,N-치환 설파모일 라디칼,니트로 라디칼, 리드록시 라디칼, 옥소 라디칼, C₁ 내지 C₄의 저급 알콕시 라디칼, 시아노 라디칼, C₁내지 C₄의 저급 알킬 카르복실레이트 라디칼, 아릴 또는 치환된 아릴 라디칼, 또는 아미노 또는, R₁및 R₂가 동일하거나 상이하며, 수소원자, 알킬 라디칼, 아릴 라디칼, 알킬 카르복시 라디칼, 아릴카르복시 라디칼, 알킬설포닐 라디칼 또는 아릴 설포닐 라디칼, 1 내지 4개의 탄소원자를 포함하는 이러한 라디칼의 알킬 단편을 나타낼 때 일반식 -의 치환된 아미노 라디칼을 나타내는 상기 일반식(Ⅰ)의 유도체 사용.
  2. 제 1항에 있어서, (1) 1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (2) 4-메틸-1-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (3) 4-니트로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (4) 4- 클로로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (5) 4-에톡시카보닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (6) 4-브로모-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (7) 4- 시아노-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (8) 4- 플로우로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (9) 4- 메톡시-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (10) 4-아미노-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (11) 4-메틸설폰아미도-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (12) 4- 벤즈 아미도-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (13) 4- 아세트아미도-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (14) 4-(2-부틸)아미노-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (15) 4-(4-메톡시페닐)-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (16) 4-(4-클로로페닐)-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (17) 4-(1-피롤릴)-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (18) 4-페닐-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (19) 4-페닐설폰아미도-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸,(20) 4-(4-메틸벤젠설폰아미도)-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (21) 4-부틸설폰아미도-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸,(22)4-프로필설폰아미도-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸,(23)4-에틸설폰아미도-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸,(24) 4-(N,N-디메틸설파모일)-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (25) 4-설포-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸, (26) 4-클로로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸 히드로클로라이드, (27)4-클로로-1-{4-[4-(2-피리미디닐)-1-피페라지닐]-부틸}-1H-피라졸 디히드로 클로라이드로 부터 선택되는 일반식(Ⅰ)의 유도체의 사용.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900019028A 1989-11-22 1990-11-22 금단 증후군의 억제제 KR950007230B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8915316A FR2654621B1 (fr) 1989-11-22 1989-11-22 Inhibition du syndrome d'abstinence.
FR8915316 1989-11-22

Publications (2)

Publication Number Publication Date
KR910009268A true KR910009268A (ko) 1991-06-28
KR950007230B1 KR950007230B1 (ko) 1995-07-07

Family

ID=9387643

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900019028A KR950007230B1 (ko) 1989-11-22 1990-11-22 금단 증후군의 억제제

Country Status (16)

Country Link
US (1) US5162323A (ko)
EP (1) EP0429360B1 (ko)
JP (1) JPH0699309B2 (ko)
KR (1) KR950007230B1 (ko)
AT (1) ATE95698T1 (ko)
AU (1) AU628237B2 (ko)
CA (1) CA2030401C (ko)
DE (1) DE69003924T2 (ko)
DK (1) DK0429360T3 (ko)
ES (1) ES2034909A6 (ko)
FR (1) FR2654621B1 (ko)
HU (1) HU207797B (ko)
NO (1) NO905028L (ko)
PT (1) PT95949B (ko)
RU (1) RU2042674C1 (ko)
ZA (1) ZA909256B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5712392A (en) * 1990-12-28 1998-01-27 Neurogen Corporation Certain 4-piperidine- and piperazinoalkyl-2-phenyl imidazole derivatives; dopamine receptor subtype specific ligands
US5681956A (en) * 1990-12-28 1997-10-28 Neurogen Corporation 4-aryl substituted piperazinylmethyl phenylimidazole derivatives; a new class of dopamine receptor subtype specific ligands
FR2671972B1 (fr) * 1991-01-25 1995-03-03 Esteve Labor Dr Utilisation de derives 1-h-azole-(omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl) pour la preparation de medicaments destines au traitement des troubles des fonctions cognitives.
FR2701260B1 (fr) * 1993-02-05 1995-05-05 Esteve Labor Dr Dérivés de 2-[4-(4-azolylbutyl)-1-pipérazinyl]-5-hydroxypyrimidine, leur préparation et leur application en tant que médicaments.
FR2705098B1 (fr) * 1993-05-10 1995-08-04 Esteve Labor Dr Procédé de préparation de 2-{4-[4-(chloro-1-pyrazolyl)butyl]1-pipérazinyl}pyrimidine (Lesopitron) .
ES2099031B1 (es) * 1995-05-31 1997-12-01 Esteve Labor Dr Nuevos polimorfos de diclorhidrato de lesopitron y sus formas hidratadas, procedimientos de preparacion y composiciones que los contienen.
US6166205A (en) * 1998-09-02 2000-12-26 Neurogen Corporation 2-Aryl-4-(1-[4-heteroaryl]piperazin-1-yl)methylimidazoles: dopamine . D.sub4 receptor subtype ligands
FR2797399B1 (fr) * 1999-08-13 2002-10-18 Aventis Pharma Sa Utilisation de la cyamemazine dans le traitement du sevrage aux benzodiazepines
ES2167276B1 (es) * 2000-10-20 2003-04-01 Esteve Labor Dr Nuevos derivados de cianoaril (o cianoheteroaril)-carbonil-piperazinil-pirimidinas, su preparacion y su aplicacion como medicamentos.
EP1749525A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti-addictive agent
WO2007009691A2 (en) * 2005-07-15 2007-01-25 Laboratorios Del Dr. Esteve, S.A. Combination of substituted pyrazolines and anti -addictive agent

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777173A (en) * 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
FR2642759B1 (fr) * 1989-02-09 1991-05-17 Laboratorios Esteve Sa Derives de pyrimidyl-piperazinyl-alkyl azoles avec activite anxiolytique et/ou tranquillisante

Also Published As

Publication number Publication date
US5162323A (en) 1992-11-10
DK0429360T3 (da) 1993-12-13
CA2030401A1 (fr) 1991-05-23
NO905028L (no) 1991-05-23
EP0429360A2 (fr) 1991-05-29
NO905028D0 (no) 1990-11-20
AU6676790A (en) 1991-05-30
KR950007230B1 (ko) 1995-07-07
PT95949B (pt) 1998-01-30
AU628237B2 (en) 1992-09-10
EP0429360A3 (en) 1991-09-25
ZA909256B (en) 1991-10-30
DE69003924D1 (de) 1993-11-18
ATE95698T1 (de) 1993-10-15
RU2042674C1 (ru) 1995-08-27
FR2654621A1 (fr) 1991-05-24
HU207797B (en) 1993-06-28
HUT56093A (en) 1991-07-29
DE69003924T2 (de) 1994-02-24
JPH0699309B2 (ja) 1994-12-07
JPH03176422A (ja) 1991-07-31
HU907230D0 (en) 1991-05-28
EP0429360B1 (fr) 1993-10-13
CA2030401C (fr) 2000-03-07
FR2654621B1 (fr) 1994-09-23
ES2034909A6 (es) 1993-04-01
PT95949A (pt) 1991-09-13

Similar Documents

Publication Publication Date Title
KR910009268A (ko) 금단 증후군의 억제
HK1026204A1 (en) Heterocyclic compounds process for their preparation and pharmaceutical compositions containing themand their use in the treatment of diabetes and related diseases.
DE69803750D1 (de) Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften
DE69413542T2 (de) Perhydroisoindolderivate als substanz p antagonisten
AP2003002825A0 (en) Pyrazole compounds useful as protein kinase inhibitors
CA2258949A1 (en) Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DK0497658T3 (da) Anvendelse af (omega-(4-(2-pyrimidinyl)-1-piperazinyl)-alkyl)-1H-azolderivater til fremstilling af lægemidler til behandling af sygdomme i de kognitive funktioner
SE9601598D0 (sv) New process
BR0007500A (pt) Composto triazol, fármaco, e, uso do composto
KR880002834A (ko) α-알킬-4-아미노-3-퀴놀린메탄올 및 1-(4-아르알킬아미노-3-퀴놀리닐) 알칸온, 이의 제조방법 및 약제로서의 용도
PT93095A (pt) Processo para a preparacao de derivados de pirimidinil-piperazinil-alquil-azois com actividade ansiolitica e/ou tranquilizante e de composicoes farmaceuticas que os contem
IL89369A (en) Substituted 2-(heterocyclylphenyl)- 1,2,4-triazine-3,5- diones, their preparation and their use
KR960028909A (ko) 항-기생충 활성
ATE16384T1 (de) Phenylpiperazinyl-propanole von hetarylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
DE69824756D1 (de) Substituierte thiazolidinedione und oxazolidinedione mit antidiabetischen,hypolipidämischen und antihypertensiven eigenschaften
EP0112587A3 (en) Derivatives of 4-(1-(phenyl)-1-(hydroxy)-prop-1-yl)-resorcine, process for their preparation and medicines containing these compounds
RU95102147A (ru) Производные 1-[2-(1н-инден-3-ил)этил]-4-(нафт-1-ил)пиперазина, способ их получения и содержащие их медикамент и фармацевтический состав
IL85640A0 (en) 1-(1-aryl-2-hydroxyethyl)-imidazoles and salts thereof,processes for the preparation thereof and pharmaceutical compositions containing them
KR950000704A (ko) 로라카베프 하이드로클로라이드 c_1-c_3 알콜 용매화물 및 그의 용도
ECSP982686A (es) Poliformo antifungico cristalino

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010626

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee